Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm

Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL • 76 pts part of bigger trial • PFS no diff but was ⬆️ when MVA performed • responses ⬆️ • BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths. Doubt there will be further development. #18ICML #ICML25 #lymsm

Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim • global Ph 1B • med age 72y • at RP2D, ORR 100%, CRR 80% • no G3+ CRS, 8% ICANs Very impressive results #18ICML #ICML25 #lymsm

Dreyfuss et al • ISRT & Pembro in localised relapsed cHL • RT dose varied according to response to Pembro • generally safe & good outcomes • did not seem to impair subseq Rx Consider for older relapsed pts #18ICML #ICML25 #lymsm

Dreyfuss et al • ISRT & Pembro in localised relapsed cHL • RT dose varied according to response to Pembro • generally safe & good outcomes • did not seem to impair subseq Rx Consider for older relapsed pts #18ICML #ICML25 #lymsm

Davison et al - PRO substudy of S1826 substudy. Interesting outputs: • NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold. • BV-AVD showed excess neuropathy which had a clinically meaningful impact. #ICML25 #lymsm

Evans et al: E-HIPI prognostic score early cHL • Holistic consortium • 1 binary factor: female sex better prog • 3 continuous: max tumour diam, Hb and albumin. Great work from Online calculator now available! #18ICML #ICML25 #lyms

Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome. Take home message: if safe to use dox then do use it! #18ICML #ICML25 #lymsm

Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL • flow cytometry based • MRD- most rapid with BR • with RCHOP, even MRD- pts do poorly • with IR, no assocn with MRD & outcome #18ICML #ICML25 #lymsm

Flerlage et al • GLOW data nod LPHL • completely resected 1A, RT assoc with ⬆️ PFS compared with observation • unresected - ABVD-RT & RT do v well • no infield relapses if RT given Great work which significantly informs practice. #18ICML #ICML25 #lymsm

Rossi et al - baseline MTV, Dmax & esp combo, assoc with PFS. Independent effect of IPSS. Both factors improve prognostic impact of iPET. Based on AHL2011 study so all have 2x eacBEACOPDac as 1st 2 cycle. #18ICML #ICML25

Herrera et al - ctDNA in S1826 • 97% ctDNA + baseline • clearance at C3D1 assoc with PFS • within pos pts, those with minor ⬇️ assoc with esp poor outcomes • EOT ctDNA detection also assoc with poor outcomes CtDNA ripe for response adapted trials. #18ICML #ICML25 #lymsm

Ahmed et al - EBV & cHL subtype in S1826 study • EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked) • non-NS histology also benefited more from NAVD. Biology is important! #lymsm #18ICML #ICML25

Things are hotting up for the first of 2 #Hodgkin lymphoma sessions today. #18ICML #ICML25 #lymsm

A no. of trials in RR DLBCL with RGemOx as comparator all show: • PFS med 2-3 mo • OS med 12-13 mo Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc. Beaten by exptl arms in StarGlo, Polargo, Sunmo Take home: no more RGemOx pls - it’s defeated! #18ICML #lymsm

Feldman et al - acimtamig (CD16/CD30 engager) with alloNK in RR #Hodgkin • 24 pts, heavily preRx • ORR 88%, CRR 58% • 25% CRS with 1 G3, no ICANs or GvH Looks very active. Interested to see how it will developed further. #18ICML

Shah et al - Zamto-cel 3L+ DLBCL • tandem CD19 / CD20 41BB construct • non cryopreserved, short vein-vein • 69 pts • ORR 73%, CRR 51% • no G3+ CRS, 4% G3+ ICANS Clearly active but is it better than current agents? #18ICML

Sancho et al - POLARGO. • RGemOx vs Pola-RGemOx R/R DLBCL • 2L+ DLBCL (no ASCT eligible if 2L) • OS primary EP: signif adv 12.5mo vs 19.5mo • PFS & CMR rate better • tox modest - ⬆️ infn & PN • no effect of cell of origin Interesting but ? value if 1L PolaRCHP #18ICML

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL. • operationally deliverable with ctDNA turnaround median 9d • low rate PET+ and ctDNA+ at interim • assessing whether acala addition benefits those with Myd88 &/or CD79b mutns SAKK38/19 trial #ICML18

@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with • exhausted T-cells • super-activated macrophages. #ICML18

Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS • 89% Nivo-AVD • 64% BV-AVD 55% discontinued BV, 14% Nivo NRM 16% BV-AVD, 6% Nivo-AVD Transformational. If only we had access! #lymsm ascopubs.org/doi/10.1200/...

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three...

ascopubs.org

Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua onlinelibrary.wiley.com/doi/10.1111/...

The role of PET/CT in peripheral T‐cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO‐T trial

A PET/CT substudy of the UK NCRI CHEMO-T phase 2 trial was performed to further investigate the role of PET/CT in previously untreated patients with peripheral T-cell lymphoma (N = 82). Our findings ...

onlinelibrary.wiley.com

It’s the unboxing of the eighth edition of Hoffbrands Postgraduate Haematology. A real honour to be an editor alongside Adam Mead, Deborah Hay, Mike Lanffan and of course Victor Hoffbrand. Do get your copy!

Delighted to be sharing the stage with the great @broeckelmann.bsky.social at the 10th International Congress on Leukemia, Lymphoma and Myeloma. An erudite overview of the 1L setting - I’ve been given relapsed disease. #lymsm

Great to see this is in print!

Radcliffe Department of Medicine@rdm.ox.ac.uk · last yr.

Our researchers Adam Mead, Graham Collins and Deborah Hay have edited the eighth edition of this seminal #haematology text book, published by Wiley. Intended as a reference work and guide to the latest research in the field. www.rdm.ox.ac.uk/news/rdm-res... @graham74gc.bsky.social

Haynes et al - also data on bispecifics in secondary CNS lymphoma. 5/9 showed some response. #BSH2025 @bsochaem.bsky.social

Update on UK real world bispecific data. ITT ORR 41% & CRR 22.2%. G3+ infn 29%. PS, prior benda & refractory to last line assoc with worse outcome. Clear that some very ill and heavily pretreated pts being given bispecifics in real world setting. Should they be? #BSH2025 @bsochaem.bsky.social

ENRICH study - fantastic data from UK study. De David Lewis. IR superior PFS compared with 1L R-chemo with most benefit coming from RCHOP comparison. #BSH2025 @christianb.bsky.social

Great talk by Davis Lewis. Should we perform ASCT in any patient with mantle cell lymphoma? He argues no - irrespective of MRD data or use of BTKi 1L. Study by Fenske et was MRD driven but only 9% MRD- & the +ve pts did about the same as the -ve. #BSH2025 @bsochaem.bsky.social